I. Lombardo

发表

The efficacy of RVT-101, a 5-ht6 receptor antagonist, as an adjunct to donepezil in adults with mild-to-moderate Alzheimer’s disease: Completer analysis of a phase 2b study

I. Lombardo, G. Ramaswamy, S. Piscitelli, 2015, Alzheimer's & Dementia.

Prefrontal Dopamine D1 Receptors and Working Memory in Schizophrenia

R. V. Van Heertum, Yiyun Huang, J. Gorman, 2002, The Journal of Neuroscience.

Serotonin transporters in obsessive-compulsive disorder: a positron emission tomography study with [11C]McN 5652

Mark Slifstein, Marc Laruelle, Dah-Ren Hwang, 2003, Biological Psychiatry.

Serotonin 1A receptor availability in patients with schizophrenia and schizo-affective disorder: a positron emission tomography imaging study with [11C]WAY 100635

Yiyun Huang, John H. Martin, D. Hwang, 2006, Psychopharmacology.

Non toxic goiter in the adult population of Genoa: 10 years of experience.

I. Lombardo, R. Armonino, B. Santaniello, 2012, Journal of preventive medicine and hygiene.

HEADWAY-DLB: A MULTINATIONAL STUDY EVALUATING THE SAFETY AND EFFICACY OF INTEPIRDINE (RVT-101) IN DEMENTIA WITH LEWY BODIES

B. Boeve, I. McKeith, D. Aarsland, 2017, Alzheimer's & Dementia.

Metabolic Risk Status and Second-Generation Antipsychotic Drug Selection: A Retrospective Study of Commercially Insured Patients

J. Newcomer, I. Lombardo, E. Morrato, 2009, Journal of clinical psychopharmacology.

Measurement of Striatal and Extrastriatal Dopamine D1 Receptor Binding Potential With [11C]NNC 112 in Humans: Validation and Reproducibility

Christer Halldin, Osama Mawlawi, Mark Slifstein, 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

Radioisotopical Studies of the Glomerular Filtrate in a Group of Insulin-Dependent Diabetics

I. Lombardo, G. Viviani, V. Lindner, 1991 .

The impact of calories and fat content of meals on oral ziprasidone absorption: a randomized, open-label, crossover trial.

M. Versavel, S. Preskorn, I. Lombardo, 2009, The Journal of clinical psychiatry.

Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis

R. Labaudinière, D. Judge, M. Maurer, 2016, Neurology and Therapy.

Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes.

R. Falk, A. Quyyumi, D. Judge, 2015, Circulation. Heart failure.

Efficacy of ziprasidone in dysphoric mania: Pooled analysis of two double-blind studies

S. Stahl, I. Lombardo, A. Loebel, 2007, European Psychiatry.

Ziprasidone for the Treatment of Acute Manic or Mixed Episodes Associated with Bipolar Disorder

I. Lombardo, A. Loebel, K. Ice, 2007, CNS drugs.

Brain serotonin transporter distribution in subjects with impulsive aggressivity: a positron emission study with [11C]McN 5652.

Mark Slifstein, Marc Laruelle, Dah-Ren Hwang, 2005, The American journal of psychiatry.

Understanding the relationship between baseline BMI and subsequent weight change in antipsychotic trials: Effect modification or regression to the mean?

D. Allison, I. Lombardo, A. Loebel, 2009, Psychiatry Research.

Serotonin Transporter Availability in Patients with Schizophrenia: A Positron Emission Tomography Imaging Study with [11C]DASB

Yiyun Huang, R. Narendran, D. Hwang, 2005, Biological Psychiatry.

Findings of a U.S. national cardiometabolic screening program among 10,084 psychiatric outpatients.

B. Druss, C. Correll, I. Lombardo, 2010, Psychiatric services.

PET Studies of Binding Competition Between Endogenous Dopamine and the D 1

R. Parsey, D. Hwang, M. Laruelle, 1999 .

PET Studies of Binding Competition between Endogenous Dopamine and the D1 Radiotracer [11C]NNC 756

Christer Halldin, Marc Laruelle, Ramin Parsey, 1998, NeuroImage.

Measurement of the serotonin 1A receptor availability in patients with schizophrenia during treatment with the antipsychotic medication ziprasidone

Yiyun Huang, John H. Martin, D. Hwang, 2011, Journal of psychopharmacology.

Occupancy of brain serotonin transporters during treatment with paroxetine in patients with social phobia: a positron emission tomography study with [11C]McN 5652

R. V. Van Heertum, Yiyun Huang, J. Gorman, 2002, Psychopharmacology.

Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia

D. Hilt, R. Keefe, I. Lombardo, 2015, Neuropsychopharmacology.

Report on ISCTM Consensus Meeting on Clinical Assessment of Response to Treatment of Cognitive Impairment in Schizophrenia

Philip D. Harvey, E. Dunayevich, D. Goff, 2015, Schizophrenia bulletin.

EARLY PSYCHOTIC RESPONSE INDEX FOR PREDICTING LONG-TERM GLOBAL FUNCTIONING IN PATIENTS WITH SCHIZOPHRENIA

S. Kapur, I. Lombardo, O. Agid, 2009 .

Two 6-Week, Randomized, Double-Blind, Placebo-Controlled Studies of Ziprasidone in Outpatients With Bipolar I Depression: Did Baseline Characteristics Impact Trial Outcome?

G. Sachs, I. Lombardo, S. Kolluri, 2012, Journal of clinical psychopharmacology.

Ziprasidone does not exacerbate mania or worsen depression during treatment of bipolar mania: An analysis of pooled clinical trial data

I. Lombardo, F. Mandel, F. Rappard, 2007, European psychiatry.

Reduction of functional disability with atypical antipsychotic treatment: A randomized long term comparison of ziprasidone and haloperidol

Philip D. Harvey, I. Lombardo, E. Pappadopulos, 2009, Schizophrenia Research.

P.3.c.056 Efficacy of ziprasidone in the treatment of schizoaffective disorder:an analysis of 2 fixed-dose, placebo-controlled trials

I. Lombardo, L. Warrington, R. Yang, 2006, European Neuropsychopharmacology.

Impact of geographical and cultural factors on clinical trials in acute mania: lessons from a ziprasidone and haloperidol placebo-controlled study.

E. Vieta, I. Lombardo, F. Mandel, 2011, The international journal of neuropsychopharmacology.

Cognitive Impairment in Patients With Bipolar Disorder

K. Burdick, R. Keefe, I. Lombardo, 2009 .